NCT04971876 is a NA clinical trial of HLR-1 in Lips Enhancement, sponsored by Hallura Ltd..

Who is sponsoring NCT04971876?

NCT04971876 is sponsored by Hallura Ltd..

What drugs are being tested in NCT04971876?

Interventions in NCT04971876: HLR-1, HLR-2, HLR-3.

What condition does NCT04971876 study?

NCT04971876 studies Lips Enhancement, Nasolabial Fold Correction, Midface Volume Deficit.

Is NCT04971876 still recruiting?

NCT04971876 is currently completed. Last updated 3 November 2022.

Last reviewed 2022-11-03 · How we verify

NCT04971876

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Safety and Performance of an Injectable Hyaluronic Acid Filler

Completed NA Last updated 3 November 2022

What this trial tests

NA trial testing HLR-1 in Lips Enhancement in 132 participants. Completed in 6 September 2022.

Timeline

27 October 2020

Primary endpoint
11 August 2022

6 September 2022

Quick facts

Lead sponsor	Hallura Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	132
Start date	27 October 2020
Primary completion	11 August 2022
Estimated completion	6 September 2022
Sites	3 locations across Germany, Poland

Drugs / interventions tested

HLR-1
HLR-2
HLR-3

Conditions studied

Lips Enhancement — all drugs for Lips Enhancement →
Nasolabial Fold Correction — all drugs for Nasolabial Fold Correction →
Midface Volume Deficit — all drugs for Midface Volume Deficit →

Sponsor

Hallura Ltd.

Who can join

21 and older, any sex, with Lips Enhancement or Nasolabial Fold Correction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the safety and performance of the investigational device in its three concentrations for cheek and lips augmentation and correction of the nasolabial folds, assuming that the performance of the product will be demonstrated based on the responder rates observed compared to baseline.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Twelve-Month Outcome of Nasolabial Fold Correction by a Novel Non-1,4-Butanediol Diglycidyl Ether, Click-Crosslinked, Long-Chain Hyaluronic Acid Product.
Safir A, Sattler S, Da Mota R, Kowalska-Olędzka E, et al · · 2026 · PMID 42029422 · DOI 10.1111/jocd.70840

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04971876 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hallura Ltd.
Last refreshed: 3 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04971876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing